Skip to Main Content
Contribute Try STAT+ Today

The pandemic crisis has illuminated a stark reality that innovators, particularly those in biotech, have long been aware of: The world is filled with great ideas that don’t have the impact they might because how to develop and scale them isn’t considered until it is either absolutely essential — or too late — to do so.

The mRNA vaccines against SARS-CoV-2 represent a perfect example of this principle. While the technology behind mRNA vaccines was developed more than 40 years ago, it took the emergency of a global pandemic for researchers to receive the support needed to bring their concept through Food and Drug Administration authorization and approval and to market. Imagine how many people might have benefited from this technology — how many lives might have been saved — had it been developed and applied earlier.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment